fool.comAUG 193 min read$ABSI

Absci (ABSI) Q2 2026 Earnings Call Transcript

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

Original reporting

fool.com

Published Aug 19, 2026, 2:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 19, 2026, 2:33 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Absci (ABSI) Q2 2026 Earnings Call Transcript — source image — Source · fool.com

Decision brief

The 30-second read

$ABSIBearishMed

Why it matters

Earnings miss and cash infusion could drive short-term volatility; long-term pipeline progress remains key.

Market read

The earnings release provides fresh financial data and financing details that may affect ABSI's stock and broader biotech sentiment.

What to watch

Potential regulatory milestones for ABS-201 could unlock significant upside beyond current earnings focus.

Relevance 7/10Novelty 8/10Timing: post-earnings release Aug 11 2026

Background

Absci Corp is a biotech company developing AI-driven therapeutics, recently raising capital and reporting Q2 results.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ABSIBearishMedium confidence

Context

Q2 2026 earnings call disclosed revenue of $0.3M, net loss of $33.2M, and a $93.6M financing round including $40M from Eli Lilly.

Expected impact

Potential near-term downside pressure with upside upside if financing is viewed positively.

Evidence & confidence

Loss widened YoY and revenue halved, but cash position improved; market reaction will hinge on financing perception.

Market effects

Sector

Highlights ongoing investment in AI-driven drug discovery within biotech sector.

Regional

US biotech investors may reassess cash burn vs financing trends.

Global

Eli Lilly's strategic investment signals larger pharma interest in AI platforms.

Counterpoint

What could challenge this read

Financing may be seen as a vote of confidence, supporting a longer-term bullish case.

Key entities

Company
Absci Corp
Biotech firm developing AI-driven drug candidates.
Strategic Investor
Eli Lilly
Provided $40M strategic investment for ABS-201 program.

Read at source ← All news

SEP 24

$ABSILow

Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis

Absci Corporation (ABSI) announced plans for a Phase 2 trial of ABS-201, an AI-designed antibody for endometriosis, expected to start in mid-2027. The trial will assess efficacy and safety in 150 patients across 10 countries, focusing on pain reduction. ABS-201 targets the prolactin receptor, offering a non-hormonal approach to treatment.

finanznachrichten.de2 min

AUG 18

$AMDMed

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

Advanced Micro Devices (AMD) filed its first 13F, revealing a $1.31 billion portfolio with six positions. Top holdings include SpaceX, Absci (ABSI), Sanmina (SANM), Nutanix (NTNX), and Quantum Computing (QUBT). AMD's Q2 revenue surged 50.1% YoY to $11.536 billion, with data center revenue doubling. AMD expects Q3 revenue of $13 billion, citing strong AI demand.

247wallst.com7 min

AUG 11

$ABSIHighAI 9/10

Why is Absci stock tumbling today?

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

investing.com3 min

AUG 11

$ABSIMed

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

SEC EDGAR 8-K6 min

JUN 26

$ABSIMed

Absci (NASDAQ:ABSI) Shares Gap Up Following Analyst Upgrade

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

themarketsdaily.com3 min

OCT 8

$005930.KSHighAI 8/10

Samsung Sees Operating Profit Topping $80 Billion Amid AI Boom -- Update

Samsung Electronics forecasted a quarterly operating profit of $80.18 billion, driven by strong demand for AI-related memory chips. This marks a nearly ninefold increase from the previous year. Revenue is also expected to hit a record at 195 trillion won. The company's stock has tripled over the past year but has faced recent volatility due to currency fluctuations and concerns about AI investment sustainability.

marketscreener.com2 min